Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467471 | 1.00 | PYGB (0.51) | PYGBGAACA12CA1CA2 | |
| SCHEMBL5838288 | 0.85 | PYGB (0.51) | PYGBGAACA12CA1CA2 | |
| SCHEMBL30239614 | 0.81 | PYGB (0.53) | PYGBGAACA12CA1CA2 | |
| SCHEMBL11508796 | 0.81 | PYGB (0.64) | PYGBGAA | |
| SCHEMBL11507282 | 0.79 | PYGB (0.61) | PYGBGAA | |
| SCHEMBL11508154 | 0.78 | PYGB (0.68) | PYGBGAA | |
| SCHEMBL11506299 | 0.78 | PYGB (0.68) | PYGBGAA | |
| SCHEMBL11507536 | 0.78 | PYGB (0.68) | PYGBGAA | |
| SCHEMBL11507426 | 0.78 | PYGB (0.67) | PYGBGAA | |
| SCHEMBL30957909 | 0.77 | PYGB (0.69) | PYGBGAACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7033765-B1 | Site-specific drug delivery | TORONTO RESEARCH CHEMICALS, INC. (CA) | 2006-04-25 | — | — | US | disclosed |
| US-20060009375-A1 | Site-specific drug delivery | TORONTO RESEARCH CHEMICALS, INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| EP-0966304-B1 | SITE-SPECIFIC DRUG DELIVERY | DIME DAVID S (CA) | 2005-05-25 | — | — | EP | disclosed |
| EP-0966304-A1 | SITE-SPECIFIC DRUG DELIVERY | Dime, David S. (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998036777-A1 | SITE-SPECIFIC DRUG DELIVERY | DIME DAVID S (CA) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009375-A1 | Site-specific drug delivery | ABCG2, ABCB1, DHFR | PYGB 1159/4885GAA 320/4885CA12 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.